Antiplatelet AMBOSS Flashcards
Glycoprotein IIb/IIIa inhibitors.
Drugs? i/v
Abciximab (Fab region fragments of monoclonal antibodies against glycoprotein IIb/IIIa receptors)
Eptifibatide
Tirofiban
Glycoprotein IIb/IIIa inhibitors. Mechanism?
Gp IIb/IIIa inhibitors bind to and block glycoprotein IIb/IIIa receptors (fibrinogen receptor) on the surface of activated platelets → prevention of platelets binding to fibrinogen → inhibition of platelet aggregation and thrombus formation
glycoprotein IIb/IIIa receptors. How they are called?
FIBRINOGEN RECEPTOR
glycoprotein IIb/IIIa receptors. Indications?
Prevention of thrombotic complications in high-risk patients with unstable angina/NSTEMI planned for PCI within 24 hours
*High risk:High-risk factors include age > 75 years; diabetes; chest pain lasting > 20 minutes; elevated troponin I (and other markers); ST depression on ECG; development of pulmonary edema; and left ventricular dysfunction.
NOT IN CAD (t.y NOT IN STABLE)
Glycoprotein IIb/IIIa inhibitors. Adverse.
Acute profound thrombocytopenia (t.y.Sudden drop in platelet count to < 50,000/mm3 within 24 hours of Gp IIb/IIIa inhibitor administration)
Hemorrhage
(Fab region fragments of monoclonal antibodies against glycoprotein IIb/IIIa receptors).
What drug?
Abciximab
!!!!Abciximab and tirofiban are contraindicated in patients with thrombocytes …………………. mm3
!!!!Abciximab and tirofiban are contraindicated in patients with thrombocytes < 100,000/mm3!
P2Y12 receptor antagonists. What agents? p/o
Clopidogrel Prasugrel Ticagrelor (reversible) Ticlopidine Cangrelor (iv)
P2Y12 receptor antagonists. Mechanism?
Inhibition of P2Y12 receptor on platelets (ADP receptor) → ↓ expression of Gp IIb/IIIa receptors (fibrinogen receptor) on platelets → inhibition of platelet aggregation
Hemostasis. Activated PLT release ADP. Whats then happens?
ADP usually binds to P2Y12 receptors, leading to activation of Gp IIb/IIIa receptors and subsequent platelet aggregation.
What P2Y12 receptor antagonists agent IRREVERSIBLE inhibition?
clopidogrel, prasugrel, ticlopidine
What P2Y12 receptor antagonists agent REVERSIBLE inhibition?
ticagrelor
P2Y12 receptor antagonists. INDICATIONS?
DUAL ANTIPLATELET THERAPY!!!! (WITH ASA - ty. aspirinu):
1. STEMI
2. Unstable angina/NSTEMI
3. Secondary prevention of cardiac events in patients post PCI and/or stenting
Before PCI
Diagnosed MI. What we prescribe from antiplatelets?
Aspirin and P2Y12 receptor antagonists are administered as soon as MI is diagnosed.
Why give dual therapy in unstable/NSTEMI?
To prevent further clot progression
Why need and how long for therapy post PCI?
Secondary prevention of cardiac events in patients post PCI and/or stenting.
Aspirin and P2Y12 receptor antagonists should be continued for at least 12 months (if tolerated) after the acute event.
We prescribe aspirin, but there is intolerance. What to prescribe then?
P2Y12 receptor antagonists.
Alternative to aspirin in cases of intolerance: to prevent recurrence of thromboembolic events, including ischemic stroke, MI, and symptomatic peripheral arterial disease.
Why antiplatelets needed in PCI?
to prevent restenosis
P2Y12 receptor antagonists. adverse 5.
Allergic reactions (rash, pruritus, anaphylaxis) Hemorrhage Gastrointestinal upset (rare) Possibly TTP (all) Ticlopidine: neutropenia/agranulocytosis
ASA versus P2Y12 receptor antagonists. Which have lower bleeding risk?
P2Y12 receptor antagonists
the risk of hemorrhage is lower than that of acetylsalicylic acid.
Neutropenia/agranulocytosis. What drugs?
ticlopidine (P2Y12 rec antag)
P2Y12 receptor antagonists. Which drug is dependent on hepatic CYP?
Clopidogrel
Activation is dependent on hepatic cytochrome P enzymes.
P2Y12 receptor antagonists. Which can have interactions in liver?
Clopidogrel - ACTIVATION is dependent on CYP, therefore not effective in individual with drug-induced inhibition of CYP enzymes (e.g., cimetidine, amiodarone, omeprazole, etc.)
Genetic polymorphisms of CYP enzymes. Which P2Y12 receptor antagonists will not work?
Clopidogrel